Larimar Therapeutics, Inc. (LRMR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Three Bala Plaza East
Bala Cynwyd, PA 19004
United States of America (the)
Phone
844 511 9056
Website
Sector
Healthcare
Industry
Biotechnology
Employees
65
First IPO Date
June 19, 2014
| Name | Title | Pay | Year Born |
| Carole S. Ben-Maimon | Chief Executive Officer, President & Director | 976,403 | 1959 |
| Gopi Shankar | Chief Development Officer | 642,351 | 1971 |
| Michael Celano | Secretary & Chief Financial Officer | 696,996 | 1959 |
| Russell G. Clayton | Chief Medical Officer | 0 | 1961 |
| Francis Michael Conway | Vice President & Controller | 0 | N/A |
| John Berman | Vice President of Finance & Administration | 0 | N/A |
| Jennifer Spokes Johansson | Vice President of Legal & Compliance | 0 | N/A |
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.